Search Results

Diurnal Ltd., a Neurocrine Biosciences company, announced that it will present new post hoc analyses of Phase 3 extension study data for modified-release hydrocortisone, which is being investigated as a treatment for adults with congenital adrenal hyperplasia, at ENDO 2023 June 15–18 in Chicago.

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi ® and Submits Market Authorization Application in Switzerland FREIENBACH, Switzerland--( BUSINESS WIRE )-- EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a

Smartlens, Inc., a clinical-stage ophthalmic technology company, has closed an oversubscribed $6.1M Series A equity financing round to advance regulatory clearance for miLens, a novel, electronics-free, soft contact lens for monitoring diurnal intraocular pressure.

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery using the OMNI® Surgical System suppressed daily fluctuations in intraocular pressure – a meaningful and independent risk factor for the progression of glaucoma.

Licensing agreement with Diurnal Group plc supports mission to provide individuals and families in China affected by rare diseases with the most effective medicines available in the world

Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has signed a licensing agreement with Diurnal Group plc (AIM: DNL), a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc (LSE AIM: DNL)